Immune responses to lentiviral vectors

Antonia Follenzi, Laura Santambrogio, Andrea Annoni

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Efficient delivery and sustained expression of a therapeutic gene into human tissues are the requisite to accomplish the high expectations of gene therapy. A major challenge has concerned development of gene transfer systems capable of efficient cell transduction and transgene expression without harm to the recipient. A lot of work has been done to demonstrate the efficacy of gene therapy in animal models that mimic situations in humans. Use of lentiviral vectors (LVs) offers multiple advantages for gene replacement therapy, because they combine efficient delivery, ability to transduce proliferating and resting cells, capacity to integrate into the host chromatin to provide stable long-term expression of the transgene, absence of any viral genes in the vector and absence of interference from preexisting viral immunity. However, one of the major barriers to stable gene transfer by LVs and other viral vectors is the development of innate and adaptive immune responses to the delivery vector and the transferred therapeutic transgene. Since this greatly hinders the therapeutical benefits of gene therapy by LVs, developing strategies to overcome the host immune response to the transfer vector and the transgene is a matter of current investigation.

Original languageEnglish (US)
Pages (from-to)306-315
Number of pages10
JournalCurrent Gene Therapy
Volume7
Issue number5
DOIs
StatePublished - Oct 2007

Fingerprint

Transgenes
Genetic Therapy
Viral Interference
Genes
Viral Genes
Adaptive Immunity
Innate Immunity
Chromatin
Immunity
Animal Models
Therapeutics

Keywords

  • Adaptive immune responses
  • Gene therapy
  • HIV-1 derived vectors
  • Innate immunity
  • Transgene

ASJC Scopus subject areas

  • Genetics

Cite this

Follenzi, A., Santambrogio, L., & Annoni, A. (2007). Immune responses to lentiviral vectors. Current Gene Therapy, 7(5), 306-315. https://doi.org/10.2174/156652307782151515

Immune responses to lentiviral vectors. / Follenzi, Antonia; Santambrogio, Laura; Annoni, Andrea.

In: Current Gene Therapy, Vol. 7, No. 5, 10.2007, p. 306-315.

Research output: Contribution to journalArticle

Follenzi, A, Santambrogio, L & Annoni, A 2007, 'Immune responses to lentiviral vectors', Current Gene Therapy, vol. 7, no. 5, pp. 306-315. https://doi.org/10.2174/156652307782151515
Follenzi, Antonia ; Santambrogio, Laura ; Annoni, Andrea. / Immune responses to lentiviral vectors. In: Current Gene Therapy. 2007 ; Vol. 7, No. 5. pp. 306-315.
@article{46b459fab89f435796e53a81637fc750,
title = "Immune responses to lentiviral vectors",
abstract = "Efficient delivery and sustained expression of a therapeutic gene into human tissues are the requisite to accomplish the high expectations of gene therapy. A major challenge has concerned development of gene transfer systems capable of efficient cell transduction and transgene expression without harm to the recipient. A lot of work has been done to demonstrate the efficacy of gene therapy in animal models that mimic situations in humans. Use of lentiviral vectors (LVs) offers multiple advantages for gene replacement therapy, because they combine efficient delivery, ability to transduce proliferating and resting cells, capacity to integrate into the host chromatin to provide stable long-term expression of the transgene, absence of any viral genes in the vector and absence of interference from preexisting viral immunity. However, one of the major barriers to stable gene transfer by LVs and other viral vectors is the development of innate and adaptive immune responses to the delivery vector and the transferred therapeutic transgene. Since this greatly hinders the therapeutical benefits of gene therapy by LVs, developing strategies to overcome the host immune response to the transfer vector and the transgene is a matter of current investigation.",
keywords = "Adaptive immune responses, Gene therapy, HIV-1 derived vectors, Innate immunity, Transgene",
author = "Antonia Follenzi and Laura Santambrogio and Andrea Annoni",
year = "2007",
month = "10",
doi = "10.2174/156652307782151515",
language = "English (US)",
volume = "7",
pages = "306--315",
journal = "Current Gene Therapy",
issn = "1566-5232",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Immune responses to lentiviral vectors

AU - Follenzi, Antonia

AU - Santambrogio, Laura

AU - Annoni, Andrea

PY - 2007/10

Y1 - 2007/10

N2 - Efficient delivery and sustained expression of a therapeutic gene into human tissues are the requisite to accomplish the high expectations of gene therapy. A major challenge has concerned development of gene transfer systems capable of efficient cell transduction and transgene expression without harm to the recipient. A lot of work has been done to demonstrate the efficacy of gene therapy in animal models that mimic situations in humans. Use of lentiviral vectors (LVs) offers multiple advantages for gene replacement therapy, because they combine efficient delivery, ability to transduce proliferating and resting cells, capacity to integrate into the host chromatin to provide stable long-term expression of the transgene, absence of any viral genes in the vector and absence of interference from preexisting viral immunity. However, one of the major barriers to stable gene transfer by LVs and other viral vectors is the development of innate and adaptive immune responses to the delivery vector and the transferred therapeutic transgene. Since this greatly hinders the therapeutical benefits of gene therapy by LVs, developing strategies to overcome the host immune response to the transfer vector and the transgene is a matter of current investigation.

AB - Efficient delivery and sustained expression of a therapeutic gene into human tissues are the requisite to accomplish the high expectations of gene therapy. A major challenge has concerned development of gene transfer systems capable of efficient cell transduction and transgene expression without harm to the recipient. A lot of work has been done to demonstrate the efficacy of gene therapy in animal models that mimic situations in humans. Use of lentiviral vectors (LVs) offers multiple advantages for gene replacement therapy, because they combine efficient delivery, ability to transduce proliferating and resting cells, capacity to integrate into the host chromatin to provide stable long-term expression of the transgene, absence of any viral genes in the vector and absence of interference from preexisting viral immunity. However, one of the major barriers to stable gene transfer by LVs and other viral vectors is the development of innate and adaptive immune responses to the delivery vector and the transferred therapeutic transgene. Since this greatly hinders the therapeutical benefits of gene therapy by LVs, developing strategies to overcome the host immune response to the transfer vector and the transgene is a matter of current investigation.

KW - Adaptive immune responses

KW - Gene therapy

KW - HIV-1 derived vectors

KW - Innate immunity

KW - Transgene

UR - http://www.scopus.com/inward/record.url?scp=35349024379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35349024379&partnerID=8YFLogxK

U2 - 10.2174/156652307782151515

DO - 10.2174/156652307782151515

M3 - Article

C2 - 17979677

AN - SCOPUS:35349024379

VL - 7

SP - 306

EP - 315

JO - Current Gene Therapy

JF - Current Gene Therapy

SN - 1566-5232

IS - 5

ER -